Share

July 12, 2016; 87 (2) Retraction

Risedronate therapy for prevention of hip fracture after stroke in elderly women; Risedronate therapy for prevention of hip fracture after stroke in elderly women. Reply from the Authors

First published July 11, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002788
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1213

Share

The Neurology® editorial office recently received a letter expressing concern about the validity of the results of this paper.1 The corresponding author, Dr. Yoshihiro Sato, responded to a request for an explanation by requesting that the paper be retracted because of scientific misconduct. Dr. Sato accepts full responsibility for this fraudulent paper and maintains that none of the coauthors participated in any misconduct and appeared as authors on an honorary basis only. The Editor retracts online and printed replies related to the article.2,3

REFERENCES

  1. 1.↵
    1. Sato Y,
    2. Iwamoto J,
    3. Kanoko T,
    4. Satoh K
    . Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;64:811–816. doi: 10.1212/01.WNL.0000152871.65027.76.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Sato Y,
    2. Iwamoto J,
    3. Kanoko T,
    4. Satoh K
    . Risedronate therapy for prevention of hip fracture after stroke in elderly women [electronic response to Poole et al.]. Neurology 2005. http://www.neurology.org/content/64/5/811/reply#neurology_el;2961.
  3. 3.↵
    1. Sato Y,
    2. Iwamoto J,
    3. Kanoko T,
    4. Satoh K
    . Risedronate therapy for prevention of hip fracture after stroke in elderly women. Reply from the Authors. Neurology 2005;65:1513. Letter. doi: 10.1212/WNL.65.9.1513.
    OpenUrlFREE Full Text
View Abstract

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me